Aclaris Therapeutics, Inc. (LON:0H8T)

Market Cap	269.19M +30.9%
Revenue (ttm)	11.71M -41.9%
Net Income	-105.40M
EPS	-0.91
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	992
Average Volume	26,808
Open	3.430
Previous Close	3.368
Day's Range	3.261 - 3.430
52-Week Range	1.058 - 4.825
Beta	0.43
RSI	48.74
Earnings Date	Feb 27, 2026

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatmen...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 64
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H8T

Financial Performance

In 2024, Aclaris Therapeutics's revenue was $18.72 million, a decrease of -40.09% compared to the previous year's $31.25 million. Losses were -$132.07 million, 49.3% more than in 2023.

Financial numbers in USD